Connect with us

Technology

Induced Pluripotent Stem Cells Market Size is Expected to Grow at a CAGR of 9.4% and Reach USD 4.6 billion by 2034: Transparency Market Research Inc.

Published

on

Induced pluripotent stem cells are experiencing strong growth due to rising research into disease models and drug discovery. 

WILMINGTON, Del., July 11, 2024 /PRNewswire/ — The global induced pluripotent stem cells industry was worth US$ 1.7 billion in 2023. By 2034, it is estimated to reach US$ 4.6 billion, expanding at a CAGR of 9.4% between 2024 and 2034. As reprogramming strategies improve, iPSCs become more feasible for many applications and more attractive to buyers.

The utilization of iPSCs in drug discovery and disease modeling is being accelerated by excessive-throughput screening technologies. Aside from heart disease, liver failure, and diabetes, iPSCs are capable of creating organ replacements. By doing so, the donor organ shortage can be addressed and the impact on affected people can be enhanced. Several wound recuperation treatments are possible with iPSCs, including those that treat excessive burns and chronic ulcers.

Cells from iPSCs can be used to develop new immunotherapies, such as CAR-T mobile treatments for cancer. Depending on the patient’s immune system, these treatment plans may enhance effectiveness and reduce side effects. Besides Parkinson’s disorder, spinal cord injuries, and macular degeneration, iPSCs can also be used to update damaged or diseased cells.

Download Sample of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30530

Induced Pluripotent Stem Cells Market Report Scope:

Report Coverage

Details 

Forecast Period  

2024-2034

Base Year  

2020-2022

Size in 2023

US$ 1.7 Bn

Forecast (Value) in 2034

US$ 4.6 Bn

Growth Rate (CAGR) 

9.4 %

No. of Pages 

156 Pages 

Segments covered 

By Cell Type, By Application, By End-user

Global Induced Pluripotent Stem Cells Market: Competitive Landscape

iPSC-based therapies can be commercialized more quickly with partnerships among educational institutions and biotech/pharmaceutical companies. By utilizing global studies networks and consortia, information can be shared, protocols are standardized, and problems can be collectively solved, propelling forward the iPSC industry.

 Key Players Profiled

Axol BioscienceCynata Therapeutics LimitedEvotec SEFate TherapeuticsFUJIFILM Cellular Dynamics Inc.NcardiaLizarBio TherapeuticsREPROCELL GlobalSumitomo Dainippon Pharma Company LimitedTakara Bio USA Inc.Thermo Fisher ScientificVertex Pharmaceuticals

Key Developments

In May 2023, Fujifilm Cellular Dynamics, a global provider of induced pluripotent stem cells (iPSC), and Novo Nordisk signed an agreement to jointly develop and commercialize iPSC-derived cell therapies targeting serious chronic conditions.In October 2023, Axol Bioscience and Sygnature Discovery were involved in a scientific collaboration to incorporate human induced pluripotent stem cells-derived microglia into vitroscreening workflows for high-content imaging.

Key Findings of the Market Report

As of 2023, diagnostic centers held the largest share of the market.In 2023, North America held the dominant position in the market.In terms of cell type, fibroblasts are likely to be the primary driver of induced pluripotent stem cell demand.The use of stem cells for regenerative medicine is expected to increase in the near future.A growing number of pharmaceutical and biotechnology companies are expected to expand their offerings. 

Global Induced Pluripotent Stem Cells Market: Growth Drivers

The development of gene-enhancing technologies, including CRISPR-Cas9, has improved the production and precision of iPSCs significantly. By using these technologies, genetic defects can be corrected, and illness fashions can be introduced.In recent years, technology has improved the ease and safety of converting somatic cells into iPSCs, allowing them to be used in medical procedures. Manufacturing and analyzing iPSCs have been streamlined by automation and high-throughput screening technology, enabling big-scale research and cutting costs.The iPSCs are crucial to growing regenerative therapies for damaged tissues and organs. A capacity solution has been developed for coronary heart disease, spinal cord injuries, and neurodegenerative diseases. In oncology and chronic illness management, iPSCs can be derived from a patient’s own cells to minimize the chance of immune rejection.Using iPSCs, researchers can build disease-specific mobile models, allowing them to study disease mechanisms and screen potential drugs more effectively. Using iPSCs reduces the reliance on animal models and improves the predictability of human responses to toxicology.

 Explore Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30530 

Global Induced Pluripotent Stem Cells Market: Regional Landscape

North America has numerous international-renowned research institutions and universities that are at the leading edge of stem cell studies. IPSCs are used in basic studies, drug discovery, and disease modeling by these establishments. The National Institutes of Health (NIH) together with government groups provide significant funding for research on iPSCs.iPSCs have been the subject of an excessive number of clinical trials throughout North America, indicating their ability to grow new therapies. Several successful trials and future cures are expected to increase demand. A stem cell bank or repository in the status quo facilitates the use of iPSCs for therapeutic and research purposes.The iPSC is a viable alternative to embryonic stem cells that bypasses many of the ethical issues associated with embryonic stem cells. Increasing public awareness about stem cell research and its benefits increases support for iPSC-based improvements.

Global Induced Pluripotent Stem Cells Market: Segmentation

Cell Type

HepatocytesFibroblastsKeratinocytesOthers (Neurons, etc.)

Application

Drug DevelopmentRegenerative MedicineToxicity TestingTissue EngineeringCell TherapyDisease Modeling

End User

HospitalsDiagnostic CentersPharmaceutical & Biotechnology CompaniesContract Research OrganizationsOthers (Academic & Research Institutes, etc.)

Region

North AmericaEuropeAsia PacificLatin AmericaMiddle East & Africa

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=30530&ltype=S 

More Trending Report by Transparency Market Research:

Geriatric Care Services Market to Grow at a 7.3% CAGR from 2023 to 2028, reaching US$ 0.7 billion: TMR ReportPreeclampsia Diagnostics Market Set to Reach USD 2.3 Billion by 2031, growing at a CAGR of 3.8%: TMR ReportMedical Case Management Market is expected to grow at a CAGR of 6.1% from 2024 to 2034 and reach US$ 12.3 Bn by the end of 2034.Lucid Dreaming Devices Market is expected to grow at a CAGR of 5.1% from 2024 to 2034 and reach US$ 196.8 Mn by the end of 2034.

About Transparency Market Research 

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. 

Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com  
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn Twitter Blog | YouTube

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/induced-pluripotent-stem-cells-market-size-is-expected-to-grow-at-a-cagr-of-9-4-and-reach-usd-4-6-billion-by-2034-transparency-market-research-inc-302194822.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Waters Corporation to Host Investor Day on March 5, 2025

Published

on

By

MILFORD, Mass., Jan. 10, 2025 /PRNewswire/ — Waters Corporation (NYSE:WAT) announced that it will host an Investor Day on Wednesday, March 5th, 2025, in New York City, starting at 8:30 AM ET.

The event will feature presentations by members of the senior management team, who will discuss business initiative achievements, new strategic priorities, and our vision for future shareholder value creation. A Q&A session will follow.

In-Person Attendance
To request in-person attendance at this event, please click here or visit the Waters Investor Relations website at https://ir.waters.com, under ‘Events’.

Webcast
A live webcast will be available the day of the event. To register for the webcast, please click here or visit the Waters Investor Relations website at https://ir.waters.com, under ‘Events’. A replay of the webcast will be available shortly after the event concludes.

About Waters Corporation
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,500 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

Caspar Tudor, Head of Investor Relations
investor_relations@waters.com

View original content:https://www.prnewswire.com/news-releases/waters-corporation-to-host-investor-day-on-march-5-2025-302348226.html

SOURCE Waters Corporation

Continue Reading

Technology

As Retail Cybercrime Surges, Plank Road Ventures To Present Technology Solutions At NRF 2025 Big Show

Published

on

By

HOBOKEN, N.J., Jan. 10, 2025 /PRNewswire/ — Credit cards and other non-cash payment methods now account for some 80% of purchasing activity, according to some reports. It’s convenient for consumers, but each retail transaction may expose vital shopper information to nation-state and other cybercriminals. Consumers are inconvenienced, while retailers may suffer reputational and financial damage.

To combat the upsurge in digital incursions, Plank Road Ventures — an eMazzanti Technologies company — will present artificial intelligence, cybersecurity best-practice and other retail solutions at the NRF (National Retail Federation) 2025 Retail’s Big Show at Booth 2306, in the Startup Hub of New York City’s Jacob K. Javits Convention Center from January 12 through January 14, 2025.

“The rise in credit card, digital and other payment methods have made retailers a rich target for cyberthieves,” warns eMazzanti Technologies President Carl Mazzanti. “POS systems, for example, can store customer information and purchase history, enabling retailers to capture the information they need to inform targeted marking campaigns and personalized shopping experiences. But POS transactions also pose an attractive target for cybercriminals, and a successful data breach will have far-reaching consequences.”

Plank Road Ventures, a global managed services provider, partners with leading companies like Microsoft, Watchguard, HP, and I3 Communications to help retailers deploy technology that improve and secure their operations and store strategies, while enhancing customer experience and engagement. Retailers can meet with trained professionals from Plank Road Ventures at the NRF 2025 Retail’s Big Show, and learn about leading-edge POS and other solutions.

About eMazzanti Technologies
eMazzanti’s team of trained, certified IT experts deliver rapid response, increased revenue growth, data security, and productivity for organizations of all sizes. The firm offers cloud and mobile solutions, multi-site technology implementations, outsourced network management, 24 x 7 support, digital marketing services, and cyber security assessments and protection services.

About Plank Road Ventures
Our team of experienced retail experts works with clients to understand their specific requirements and recommend the best options. Specializing in store operations and support, the team is available 24x7x 365.

View original content:https://www.prnewswire.com/news-releases/as-retail-cybercrime-surges-plank-road-ventures-to-present-technology-solutions-at-nrf-2025-big-show-302348181.html

SOURCE Plank Road Ventures

Continue Reading

Technology

Kevin Lanouette Named Senior Vice President and General Counsel

Published

on

By

BEDFORD, Mass., Jan. 10, 2025 /PRNewswire/ — iRobot Corp. (NASDAQ: IRBT), a leader in consumer robots, today announced that Kevin Lanouette has been named Senior Vice President and General Counsel, effective January 17, 2025. Tonya Drake, the Company’s Executive Vice President and General Counsel, will transition to an advisory role ending March 7, 2025.

“I’d like to thank Tonya for her many years of service to iRobot,” said Gary Cohen, iRobot CEO. “Her legacy of tenacity and rigor in protecting the iRobot Company and our brand has been exemplary.”

“Kevin is a seasoned and highly skilled attorney whose experience in advising on complex corporate and securities, commercial, M&A and IP protection matters will be invaluable as we execute our strategic initiatives and work toward a return to profitable growth,” said Cohen.

Formerly, Mr. Lanouette was a Partner at OutsideGC, a Boston-based law firm, where he specialized in providing strategic legal counsel to clients at all stages of development and across a broad range of industries, including technology development, software and services and healthcare. Previously, he served as Assistant General Counsel at Analog Devices, Inc., a leading global semiconductor manufacturer, from 2006 to 2020, where he had responsibility for several critical legal functions, including corporate, SEC and securities matters, IP licensing and technology transfers, M&A and investments, global commercial transactions, and governance and compliance issues.

He is a graduate of the University of Maine and Harvard Law School.

About iRobot Corp.
iRobot is a global consumer robot company that designs and builds thoughtful robots and intelligent home innovations that make life better. iRobot introduced the first Roomba robot vacuum in 2002. Today, iRobot is a global enterprise that has sold more than 50 million robots worldwide. iRobot’s product portfolio features technologies and advanced concepts in cleaning, mapping and navigation. Working from this portfolio, iRobot engineers are building robots and smart home devices to help consumers make their homes easier to maintain and healthier places to live. For more information about iRobot, please visit www.irobot.com

For iRobot Investors
Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to iRobot Corporation’s expectations concerning executive transitions and execution of the company’s strategy. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. iRobot undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by iRobot, see the disclosure contained in our public filings with the Securities and Exchange Commission including, without limitation, our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kevin-lanouette-named-senior-vice-president-and-general-counsel-302348314.html

SOURCE iRobot Corporation

Continue Reading

Trending